Skip to content
What Causes What
MECHANISM? CONDITIONAL

Omega-3 supplementation → Major cardiovascular events

Higher Omega-3 supplementation moves Major cardiovascular events only in some conditions. Read the mechanism.

Assigned 4 g a day of icosapent ethyl cut a five-part ischemic composite in 8179 statin-treated adults with high triglycerides (Bhatt 2019, hazard ratio 0.75); the same dose of mixed EPA plus DHA carboxylic acids did not in 13,078 similar adults (Nicholls 2020, 0.99), and about 400 mg of EPA-DHA in margarine did not after a heart attack (Kromhout 2010).

Randomized trial · Contested · N=8179

Supported by an experiment or a tightly identified design. Read the caveats.

Mechanism

The authors treat marine omega-3 as an anti-inflammatory, triglyceride-lowering fat that might stabilize plaque. Bhatt's bottle is purified EPA as an ethyl ester. Nicholls's bottle mixes EPA and DHA as free fatty acids. Kromhout's margarine is a food-level dose. They do not agree which molecule, which dose, or which comparator does the work. Bhatt, Steg, Miller and colleagues (REDUCE-IT, 2019) assigned 8179 adults on a statin, triglycerides 135 to 499 mg per deciliter, LDL 41 to 100, and either prior cardiovascular disease or diabetes plus other risk, to 4 g a day of icosapent ethyl or mineral-oil placebo. Median follow-up was 4.9 years. A first event in the five-part composite (cardiovascular death, nonfatal infarction, nonfatal stroke, coronary revascularization, or unstable angina) occurred in 17.2 percent on EPA and 22.0 percent on placebo (hazard ratio 0.75, 0.68 to 0.83). The three-part hard composite sat at 0.74 (0.65 to 0.83). Cardiovascular death sat at 0.80 (0.66 to 0.98). Nicholls, Lincoff, Garcia and colleagues (STRENGTH, 2020) assigned 13,078 statin-treated adults with high triglycerides and low HDL in 22 countries to 4 g a day of EPA plus DHA carboxylic acids or corn oil. The trial stopped after 1,384 of a planned 1,600 events. The same five-part composite occurred in 785 (12.0 percent) on omega-3 and 795 (12.2 percent) on corn oil (0.99, 0.90 to 1.09). Gastrointestinal events were 24.7 versus 14.7 percent. New atrial fibrillation was 2.2 versus 1.3 percent. Kromhout, Giltay, Geleijnse and the Alpha Omega group (2010) assigned 4,837 people aged 60 to 80 with a prior infarction to one of four margarines for 40 months. Daily EPA-DHA intake was about 376 mg. A major event occurred in 13.9 percent. EPA-DHA sat at 1.01 (0.87 to 1.17). Plant ALA sat at 0.91 (0.78 to 1.05).

Caveats

Researchers assigned people to a bottle or a control, so this is a trial stamp. The sign is not one sign. Extra papers do not settle the claim. REDUCE-IT used mineral oil. That placebo can raise LDL and C-reactive protein. STRENGTH used corn oil and saw no event benefit. Whether the gap is EPA versus mixed n-3, ethyl ester versus carboxylic acid, or the comparator, this page does not settle. Both large trials enrolled people already on a statin, with high triglycerides. About 71 percent of REDUCE-IT was secondary prevention. STRENGTH was 70 percent diabetes. Alpha Omega was a low margarine dose after a heart attack on modern therapy. None of these is a grocery fish-oil capsule in a healthy adult. Atrial fibrillation rose on both high-dose bottles. REDUCE-IT also saw more bleeding. Those signals are not the primary count and do not flip the page to a claim that every omega-3 bottle prevents a heart attack. This is a journal entry, not medical advice and not a reason to start or stop a capsule.

Effect

qualitative. Bhatt REDUCE-IT HR 0.75 (0.68-0.83), 17.2 vs 22.0%, N=8179. Nicholls STRENGTH HR 0.99 (0.90-1.09), 785 vs 795, N=13078. Kromhout Alpha Omega EPA-DHA HR 1.01 (0.87-1.17), N=4837. Sign depends on bottle.

Nodes

Lifestyle & environmentOmega-3 supplementationBiology & endocrinologyMajor cardiovascular events

Named confounders

Cite this page

What Causes What. “Omega-3 supplementation → Major cardiovascular events.” https://whatcauseswhat.org/edges/e-omega3-cv (atlas updated 2026-09-02).

https://whatcauseswhat.org/edges/e-omega3-cv

Papers